Plain-English translation of NCT07391670 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing durvalumab, a medicine that helps your immune system fight cancer, given as an injection under your skin instead of through an IV. Researchers want to find the right dose and confirm it is safe and effective for people with certain solid tumors, including lung cancer and liver cancer. This is an early-stage study (Phase I) to see how your body handles this new way of giving the medication.
Currently, this medicine is given through an IV infusion, which requires visits to a clinic or hospital. Researchers believe giving the medication as an injection under the skin could be more convenient for patients and easier to manage, so they are testing whether this approach works as well.
You likely qualify if…
You likely don't qualify if…
The study has two parts. In the first part, researchers will test two different doses of the medication to find the safest and most effective dose. In the second part, they will give the chosen dose to more people with liver cancer to confirm it works. You will receive the medication as an injection under your skin, followed by infusions through an IV at scheduled intervals. You will have regular visits for blood tests and scans to monitor how you are responding and check for side effects.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
Australia
Georgia